Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
STStoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. (STOK)

NASDAQ Global Select · Currency in USD
$25.04 ▼ -0.66 (-2.57%)
At close: Oct 23, 4:00 PM ET. Market closed.
$25.04 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$25.70
Open
$25.53
Day's Range
$24.80 – $25.53
52 Week Range
$20.32 – $40.22
Volume
2,156,224
Avg. Volume
969,661
Market Cap
$1.62B
Beta (5Y Monthly)
1.26
PE Ratio (TTM)
--
EPS (TTM)
-$3.15
Earnings Date
Oct 29, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$51.00

Profile: Stoke Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
170
CEO
Ian F. Smith

Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression.

Earnings

Next report: Thu, Oct 29, 2026
EPS estimate -$0.93 · Revenue est. $8.21M
DateEst.Actual
Aug 3, 2026-$0.80-$0.93Miss
May 7, 2026-$0.80-$0.79Beat
Mar 16, 2026-$0.75-$0.97Miss
Nov 4, 2025-$0.54-$0.65Miss
Aug 12, 2025-$0.57-$0.40Beat
May 13, 2025-$0.37$1.90Beat

Analyst view

Consensus price target
$51.00 ▲ +103.7%
Range $44.00 – $58.00
Rating: Buy
Buy 81% · Hold 19% · Sell 0%

Get free alerts on STOK and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.